{"doi":"10.1371/journal.pone.0180761","title":"Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment","abstract":null,"journal":"PLOS ONE","year":2017,"id":631896,"datarank":3.9130384832573126,"base_score":4.31748811353631,"endowment":4.31748811353631,"self_citation_contribution":0.6476232170304466,"citation_network_contribution":3.2654152662268663,"self_endowment_contribution":0.6476232170304466,"citer_contribution":3.2654152662268663,"corpus_percentile":null,"corpus_rank":null,"citation_count":74,"citer_count":64,"citers_with_citation_signal":49,"citers_with_endowment":49,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1637692,"name":"Patrik Medstrand","orcid":null,"position":1,"is_corresponding":false},{"id":879911,"name":"Aylin Yilmaz","orcid":"0000-0001-7612-5828","position":2,"is_corresponding":false},{"id":1637693,"name":"Per-Erik Isberg","orcid":null,"position":3,"is_corresponding":false},{"id":364406,"name":"Magnus Gisslén","orcid":"0000-0002-2357-1020","position":4,"is_corresponding":false},{"id":707957,"name":"Per Björkman","orcid":"0000-0002-3697-9375","position":5,"is_corresponding":false},{"id":1249841,"name":"Olof Elvstam","orcid":"0000-0003-3799-9869","position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Virological failure and all-cause mortality in HIV-positive adults with low-level viremia during antiretroviral treatment","abstract":"OBJECTIVE: Although most HIV-infected individuals achieve undetectable viremia during antiretroviral therapy (ART), a subset have low-level viremia (LLV) of varying duration and magnitude. The impact of LLV on treatment outcomes is unclear. We investigated the association between LLV and virological failure and/or all-cause mortality among Swedish patients receiving ART. METHODS: HIV-infected patients from two Swedish HIV centers were identified from the nationwide register InfCare HIV. Subjects aged ≥15 years with triple agent ART were included at 12 months after treatment initiation if ≥2 following viral load measurements were available. Patients with 2 consecutive HIV RNA values ≥1000 copies/mL at this time point were excluded. Participants were stratified into four categories depending on viremia profiles: permanently suppressed viremia (<50 copies/mL), LLV 50-199 copies/mL, LLV 200-999 copies/mL and viremia ≥1000 copies/mL. Association between all four viremia categories and all-cause death was calculated using survival analysis with viremia as a time-varying covariate, so that patients could change viremia category during follow-up. Association between the three lower categories and virological failure (≥2 consecutive measurements ≥1000 copies/mL) was calculated in a similar manner. RESULTS: LLV 50-199 copies/mL was recorded in 70/1015 patients (6.9%) and LLV 200-999 copies/mL in 89 (8.8%) during 7812 person-years of follow-up (median 6.5 years). LLV 200-999 copies/mL was associated with virological failure (adjusted hazard ratio 3.14 [95% confidence interval 1.41-7.03, p<0.01]), whereas LLV 50-199 copies/mL was not (1.01 [0.34-4.31, p = 0.99]; median follow-up 4.5 years). LLV 200-999 copies/mL had an adjusted mortality hazard ratio of 2.29 (0.98-5.32, p = 0.05) and LLV 50-199 copies/mL of 2.19 (0.90-5.37, p = 0.09). CONCLUSIONS: In this Swedish cohort followed during ART for a median of 4.5 years, LLV 200-999 copies/mL was independently associated with virological failure. Patients with LLV had higher rates of all-cause mortality, although not statistically significant in multivariate analysis.","is_dataset_classified":null,"base_score":4.31748811353631,"endowment":4.31748811353631,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"28683128","pmcid":"PMC5500364","openalex_id":"https://openalex.org/W2731882942","authors":[],"funders":[{"funder_name":"Sahlgrenska Universitetssjukhuset","grant_id":"ALFGBG-430271","title":null}],"total_grants":1,"fwci":3.8762,"citation_percentile":0.94341757,"influential_citations":0,"citation_trend":[{"year":2018,"count":1},{"year":2019,"count":11},{"year":2020,"count":13},{"year":2021,"count":9},{"year":2022,"count":12},{"year":2023,"count":13},{"year":2024,"count":5},{"year":2025,"count":7},{"year":2026,"count":3}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0180761&type=printable","host_type":"journal"},{"url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0180761&type=printable","host_type":"publisher"},{"url":"http://dx.plos.org/10.1371/journal.pone.0180761","host_type":"publisher"},{"url":"https://doi.org/10.1371/journal.pone.0180761","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/28683128","host_type":"repository"},{"url":"https://doaj.org/article/1f0216762cb74efca2647817666c9c96","host_type":"repository"},{"url":"https://figshare.com/articles/journal_contribution/Virological_failure_and_all-cause_mortality_in_HIV-positive_adults_with_low-level_viremia_during_antiretroviral_treatment/5180902","host_type":"repository"},{"url":"https://lup.lub.lu.se/record/f21ea8db-a706-4f81-9b47-f40dd3ee8b0b","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/5500364","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC5500364","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC5500364?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["HIV/AIDS drug development and treatment","HIV Research and Treatment","HIV/AIDS Research and Interventions"],"mesh_terms":["Adult","Cause of Death","Female","Humans","Male","Middle Aged","Sweden","Viremia","HIV Infections","Anti-HIV Agents","Viral Load"],"keywords":["Viremia","Antiretroviral treatment","Antiretroviral therapy","Human immunodeficiency virus (HIV)","Medicine","Virology","Viral load"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-06T01:01:25.855491Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}